explore -WSS

explore

author：Wikipedia 2025-08-10 11:42:25 - browse：55

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Biotech lab space demand falls sharply

focus

WSS

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

CDC advisers recommend seasonal use of Pfizer RSV shot

Changes to biosimilar regulatory framework must prioritize patients

Carvykti CAR

Ukraine and a new approach to mental health in war

CDC's new outbreak response network to include Northeastern

leisure time

explore

Wikipedia

Peter Hotez and the public health issue of online harassment

Christmas in the PICU brings some surprising joy

Wildfire smoke exposes gaps in outdoor worker protections

Experts study whether long Covid risk adds up with each reinfection

After affirmative action ruling, medical educators look to 'holistic review'

Hearing on Medicare drug price negotiation gets unusually heated

Cancer drug shortages should be causing more outrage

SEC charges former device maker CEO with $41 million fraud

Continuity nursing helped my family in our darkest PICU moments

Albert Bourla of Pfizer: worst biopharma CEO of 2023

leisure time

What Congress can do to address the rural doctor shortage

Can sheer will power keep patients alive in their dying hours?

STAT Virtual Event: Putting AI to the Test

Why health records don't always know when patients are dead

Why health records don't always know when patients are dead

Drinking less cuts risk of oral cavity, esophageal cancer: Report

focus

focus

focus

focus